Clinical trials: Dose-response Relationship
Pneumonia, Pneumocystis Carinii, HIV Infections
A Double-Blind Study To Evaluate the Long-Term Safety and Effectiveness of 60 mg Versus 120 mg of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients
To evaluate the safety, tolerability, and description of time to Pneumocystis carinii pneumonia (PCP) for long-term biweekly administration of 1 of 2 doses of aerosol pentamidine when used as a prophylactic agent in patients who…
- Trial name
- NCT00002054
- Testing
- Pentamidine isethionate
- Where
- United States
- Sponsor
- Fisons
HIV Infections
The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients
To evaluate the safety of single and multiple doses (28 daily doses) of 9-[2-(R)-[[bis[[(isopropoxycarbonyl)- oxy]methoxy]phosphinoyl]methoxy]propyl]adenine fumarate (PMPA) prodrug administered orally to HIV-infected patients.
- Trial name
- NCT00002396
- Testing
- Tenofovir disoproxil fumarate
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Gilead Sciences
Healthy
Study of Galunisertib in Healthy Participants
The study involves a single dose of galunisertib taken by mouth by Japanese participants and non-Japanese participants. The study will evaluate the relationship between the effect of the study drug on the electrical activity of…
- Trial name
- NCT02752919
- Testing
- Galunisertib
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
HIV Infections
A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults
The purpose of this study is to see if it is safe and effective to give T-20, a new type of anti-HIV drug, with a combination of other anti-HIV drugs.
- Trial name
- NCT00002239
- Testing
- Enfuvirtide, Ritonavir, Abacavir sulfate
- Where
- 20 sites in United States
- Volunteers
- 68 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia
Dose-response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia
The objective of this study is demonstrate efficacy and a dose-response in the treatment of acute exacerbation of schizophrenia in comparison to placebo.
- Trial name
- NCT00580125
- Testing
- PF-00217830, Aripiprazole
- Where
- 26 sites in United States, India and 2 more
- Volunteers
- 164 people
- Sponsor
- Pfizer
Bipolar Disorder, Mood Disorders
A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety of 3 different doses of paliperidone extended release (ER) compared to placebo in patients diagnosed with Bipolar I Disorder who are experiencing an acute…
- Trial name
- NCT00299715
- Testing
- Paliperidone extended-release
- Volunteers
- 473 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Dry Age-related Macular Degeneration
QA102 Phase II Study in Subjects With Dry AMD
This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of soft drusen, visual acuity (VA)…
- Trial name
- AMEND (NCT05536752)
- Testing
- QA102
- Where
- 29 sites in United States
- Volunteers
- 150 people
- Sponsor
- Smilebiotek Zhuhai Limited
HIV Infections
A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients
To determine the tolerance and antiviral response of two different doses of atevirdine mesylate (U-87201E) in symptomatic HIV-positive patients with CD4 counts of 50-350 cells/mm3, who also take zidovudine (AZT).
- Trial name
- NCT00002322
- Testing
- Atevirdine mesylate, Zidovudine
- Where
- 12 sites in United States
- Sponsor
- Pharmacia and Upjohn
HIV Infections
An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2
To establish the relationship between the oral dose of zidovudine (AZT) and its hematologic toxicity. AZT has preliminarily been shown to decrease significant events and death in a group of AIDS / Pneumocystis carinii pneumonia…
- Trial name
- NCT00002023
- Testing
- Zidovudine
- Where
- United States
- Sponsor
- Glaxo Wellcome
Systemic Inflammatory Response Syndrome, C.Surgical Procedure; Cardiac
Studying Complement Inhibition in Complex Cardiac Surgery
The trial enrolls patients undergoing a complex cardiac surgery. The primary goal of the trial is to evaluate the pharmacodynamic dose response relationship of the monoclonal antibody IFX-1 in these patients.
- Trial name
- CARDIAC (NCT02866825)
- Testing
- IFX-1
- Where
- 10 sites in Germany
- Volunteers
- 116 people
- Sponsor
- InflaRx GmbH
HIV Infections
A Study of CI-1012 in HIV-Infected Patients
The purpose of this study is to see if it is safe and effective to give CI-1012 to HIV-infected patients who do not have any symptoms of the disease. This study also examines how the body handles CI-1012.
- Trial name
- NCT00002196
- Testing
- CI-1012
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Parke-Davis
HIV Infections
A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3
PART I: To evaluate the safety, tolerance, efficacy, and pharmacokinetics of three fixed doses of delavirdine mesylate (DLV) in combination with zidovudine (AZT) versus AZT alone in HIV-positive patients.
- Trial name
- NCT00002124
- Testing
- Delavirdine mesylate, Lamivudine, Zidovudine
- Where
- 88 sites in United States, Puerto Rico
- Volunteers
- 1,250 people
- Sponsor
- Pharmacia and Upjohn
HIV Infections, HIV Seronegativity
Safety and Effects of Giving a New HIV Vaccine (GENEVAX-HIV) to HIV-Negative Volunteers
The purpose of this study is to see if it is safe to give GENEVAX-HIV, a new HIV vaccine, to HIV-negative volunteers. This study will also look at how this vaccine affects the immune system of these volunteers.
- Trial name
- NCT00002231
- Testing
- APL 400-003
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth-Lederle Vaccines
Anorexia, Cachexia
A Study of Different Doses of Megestrol Acetate in Patients With AIDS Who Have Anorexia and Malnutrition
To compare the effects of megestrol acetate and placebo on body weight, anorexia, cachexia, calorie intake, and nutritional parameters of patients with a confirmed diagnosis of AIDS.
- Conditions
- Anorexia, Cachexia, HIV Infections
- Trial name
- NCT00002300
- Testing
- Megestrol acetate
- Where
- 15 sites in United States
- Sponsor
- Bristol-Myers Squibb
Infertility
A Dose-response Trial Using FE 999049 in Japanese Women Undergoing in Vitro Fertilisation (IVF) / Intracytoplasmic Sperm Injection (ICSI) Treatment
This trial investigates the effects of several doses of FE 999049 in Japanese women undergoing IVF/ICSI treatment.
- Trial name
- NCT02309671
- Testing
- FE 999049, follitropin beta
- Where
- Japan
- Volunteers
- 159 people
- Sponsor
- Ferring Pharmaceuticals
Type 2 Diabetes Mellitus and Microalbuminuria
A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria
The purpose of this study is to test the efficacy and safety on daily oral doses of TAK-272 5 mg, 20 mg, 40 mg and 80 mg in patients with type 2 diabetes mellitus and microalbuminuria by randomized, double-blind…
- Trial name
- NCT02332824
- Testing
- TAK-272, Candesartan cilexetil
- Where
- 68 sites in Japan
- Volunteers
- 415 people
- Sponsor
- Takeda
Heart Failure
QUantum Genomics Incremental Dosing in Heart Failure - QUID-HF
Heart Failure (HF) a common clinical condition characterized by either by a heart that does not pump sufficiently or becomes stiff. A variety of mechanisms contribute to progressive cardiac remodeling and dysfunction.
- Trial name
- QUID-HF (NCT02780180)
- Testing
- QGC001
- Where
- 23 sites in Czechia, France and 6 more
- Volunteers
- 23 people
- Sponsor
- Quantum Genomics SA
HIV Infections
A Comparison of Two Dose Levels of Indinavir Combined With Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients
The purpose of this study is to determine if two dose levels of indinavir combined with two nucleoside analogue reverse transcriptase inhibitors (NRTIs) have the same effect on plasma viral load (level of HIV in the blood).
- Trial name
- NCT00002406
- Testing
- Indinavir sulfate
- Where
- 29 sites in United States
- Volunteers
- 350 people
- Sponsor
- Merck Sharp & Dohme LLC
Obesity
Japanese Dose-Response Study of Rimonabant in Obese Patients
The primary objective is to verify the dose-response relationship of rimonabant on body weight change. The secondary objectives are to compare the effect of 3 doses of SR141716 to placebo, on body weight loss and on secondary…
- Trial name
- NCT00459004
- Testing
- rimonabant (SR141716)
- Where
- Japan
- Volunteers
- 527 people
- Sponsor
- Sanofi
HIV Infections
Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment
The purpose of this study is to look at the safety and effectiveness of an experimental protease inhibitor (a type of anti-HIV drug) called BMS-232632.
- Trial name
- NCT00004584
- Testing
- Atazanavir, Ritonavir, Saquinavir
- Where
- 38 sites in United States, Canada and 3 more
- Sponsor
- Bristol-Myers Squibb